Janney Montgomery Scott LLC Lowers Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janney Montgomery Scott LLC lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,053 shares of the medical equipment provider’s stock after selling 2,157 shares during the period. Janney Montgomery Scott LLC’s holdings in Lantheus were worth $1,542,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LNTH. Signaturefd LLC grew its holdings in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the period. Silverberg Bernstein Capital Management LLC grew its stake in Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after buying an additional 100 shares during the period. UMB Bank n.a. increased its position in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares during the period. Finally, Moody National Bank Trust Division lifted its holdings in shares of Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after acquiring an additional 162 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on LNTH shares. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. B. Riley upped their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Finally, Truist Financial restated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Trading Up 1.4 %

NASDAQ:LNTH opened at $80.84 on Friday. The firm has a market capitalization of $5.62 billion, a PE ratio of 13.45 and a beta of 0.51. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The stock has a 50 day moving average of $105.46 and a 200-day moving average of $96.17.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.